Efficacy of Artesunate versus a Combination of Artesunate and Quinine Di-Hydrochloride Given Intravenously for the Treatment of Malaria; A Comparative Study DOI
Asma Akbar, Irum Jabeen,

Kiran Kanwal

et al.

Pakistan Journal of Health Sciences, Journal Year: 2024, Volume and Issue: unknown, P. 57 - 61

Published: Nov. 30, 2024

In developing countries, malaria is still one of the leading causes morbidity and mortality. Objectives: To evaluate efficacy intravenous artesunate alone versus combination quinine. Methods: This randomized control trial was conducted in Pediatric Medicine Unit-2, Allama Iqbal Teaching Hospital, Dera Ghazi Khan, Pakistan. The inclusion criteria were children either gender, aged 2-14 years admitted to emergency department with diagnosis severe malaria. Children randomly allocated two treatment groups equal size. group received administered intravenously for a maximum 7 days. quinine combined di-hydrochloride they employing lottery method. outcome measured as number hours elapsed an individual become fever-free (temperature below 36.8°C). Results: total 104 mean duration required 28.3 ± 5.4 26.5 6.4 (p=0.1242). most frequent treatment-related side effects nausea, loss appetite, hypoglycemia, diarrhea, rash, noted 21 (20.2%), 13 (12.5%), 11 (10.6%), 5 (4.8%), 2 (1.9%) patients, respectively. Conclusions: It concluded that together did not provide any additional benefit or synergistic effect over treating children.

Language: Английский

Severe malaria intervention status in Nigeria: workshop meeting report DOI Creative Commons

Emmanuel Shekarau,

Miriam Uzoanya,

Nnenna Ogbulafor

et al.

Malaria Journal, Journal Year: 2024, Volume and Issue: 23(1)

Published: June 5, 2024

Abstract Nigeria accounts for 39% of global malaria deaths in children under 5 years age and the effective management severe is a health priority. The Annual Severe Malaria Stakeholders Workshop, held on 5–6th July 2023 Abuja, brought together representatives from 36 States, Federal Capital Territory, other key stakeholders to address across all levels service. Aims were provide updates review progress activities, burden disease, commodity logistics management, pre-referral national policy implementation as well disseminate research findings. Two roundtable discussions conducted identify challenges, barriers, facilitators Nigeria. A challenge was limited awareness updated guidelines strategic documents among frontline workers, leading misuse non-recommended medications, like α-β-arteether. Further this, need ensure appropriate treatments during pregnancy adoption WHO directive use rectal artesunate highlighted. To these issues, innovative dissemination channels guideline recommended collaboration with professional organizations enrich training materials emphasized. Other areas improvement considered processes involved insufficient coordination government agencies, inadequate referral linkages, human resources identified barriers. Recommendations focused practical measures minimize wastage injectable artesunate, enhance data through scaling up electronic medical records, strengthen systems. extension surveillance patients older than also proposed. deliver changes, actionable plans sustained recruitment are needed, committed advocacy at timely fund disbursement institutional support. overarching theme workshop that multifaceted approach needed Nigeria, emphasizing collaborative efforts, evidence-based practices, resource allocation. With largest globally, potential impact addressing challenges cannot be understated must urgently addressed.

Language: Английский

Citations

4
Assessment of efficacy and safety of imatinib as an adjunct host-targeted therapy for parasite clearance in chloroquine-resistant malaria: a prospective case control study DOI Creative Commons

Fazeel Zubair Ahmed,

Pavagada Shaifulla

The Egyptian Journal of Internal Medicine, Journal Year: 2025, Volume and Issue: 37(1)

Published: Jan. 9, 2025

Abstract Overview Chloroquine-resistant malaria poses a significant treatment challenge, especially in endemic areas. Host-targeted therapies, like tyrosine kinase inhibitors (TKIs) such as imatinib, have shown potential to improve outcomes by disrupting parasite egress from red blood cells. This study investigates the efficacy and safety of imatinib an adjunct therapy accelerate fever reduction clearance male patients with chloroquine-resistant malaria. Patients methods open-label, prospective, randomized case–control was conducted on 60 aged 18–50, diagnosed at Viswabharathi Medical College, India. were into two groups: control group receiving standard anti-malarial test plus (400 mg daily for 3 days). Efficacy endpoints included time reduce load half normalization body temperature. Safety assessments monitored adverse reactions throughout period. Results The demonstrated significantly faster fever, day 2 compared ( p < 0.05). Parasite counts decreased more rapidly group, mean levels falling below 1000 parasites/mcl 3. Mild effects, primarily headaches gastrointestinal symptoms, reported but resolved no severe events directly attributed imatinib. Conclusion Imatinib may enhance treatments accelerating cases These findings support further investigation TKIs complementary approach existing treatments, particularly regions facing drug resistance challenges.

Language: Английский

Citations

0
New therapeutic strategies for malaria DOI
Alessandro S. Pinheiro, Patrícia R. M. Rocco, Celso Caruso‐Neves

et al.

Biophysical Reviews, Journal Year: 2025, Volume and Issue: unknown

Published: March 8, 2025

Language: Английский

Citations

0
A Severe Case of Plasmodium falciparum Malaria in a 44-Year-Old Caucasian Woman on Return to Western Romania from a Visit to Nigeria DOI Creative Commons
Alin Gabriel Mihu, Rodica Lighezan, Daniela Adriana Oatis

et al.

Life, Journal Year: 2024, Volume and Issue: 14(11), P. 1454 - 1454

Published: Nov. 9, 2024

Malaria is currently the most prevalent life-threatening infectious disease in world. In this case report, we present a 44-year-old Caucasian woman with low level of education and no significant past medical history who presented to emergency room Emergency County Hospital Arad, Romania, general affected state, fever 38.5 °C, chills, weakness, headache, muscle pain, nausea, icterus, watery diarrheal stool. A viral infection was initially suspected, patient transferred Infectious Diseases Department. The anamnesis revealed that traveled Nigeria (Ado Ekiti) returned Romania 14 days before presenting hospital without following antimalarial prophylaxis. peripheral blood smear conducted parasitemia ring forms

Language: Английский

Citations

1
MALARIA PARASITE DETECTION IN RED BLOOD CELLS WITH ROULEAUX FORMATION MORPHOLOGY USING YOLOv9 DOI
Fatima Abdullahi Muhammad, Rubita Sudirman,

Nor Aini Zakaria

et al.

Tissue and Cell, Journal Year: 2024, Volume and Issue: 93, P. 102677 - 102677

Published: Dec. 18, 2024

Language: Английский

Citations

0
Efficacy of Artesunate versus a Combination of Artesunate and Quinine Di-Hydrochloride Given Intravenously for the Treatment of Malaria; A Comparative Study DOI
Asma Akbar, Irum Jabeen,

Kiran Kanwal

et al.

Pakistan Journal of Health Sciences, Journal Year: 2024, Volume and Issue: unknown, P. 57 - 61

Published: Nov. 30, 2024

In developing countries, malaria is still one of the leading causes morbidity and mortality. Objectives: To evaluate efficacy intravenous artesunate alone versus combination quinine. Methods: This randomized control trial was conducted in Pediatric Medicine Unit-2, Allama Iqbal Teaching Hospital, Dera Ghazi Khan, Pakistan. The inclusion criteria were children either gender, aged 2-14 years admitted to emergency department with diagnosis severe malaria. Children randomly allocated two treatment groups equal size. group received administered intravenously for a maximum 7 days. quinine combined di-hydrochloride they employing lottery method. outcome measured as number hours elapsed an individual become fever-free (temperature below 36.8°C). Results: total 104 mean duration required 28.3 ± 5.4 26.5 6.4 (p=0.1242). most frequent treatment-related side effects nausea, loss appetite, hypoglycemia, diarrhea, rash, noted 21 (20.2%), 13 (12.5%), 11 (10.6%), 5 (4.8%), 2 (1.9%) patients, respectively. Conclusions: It concluded that together did not provide any additional benefit or synergistic effect over treating children.

Language: Английский

Citations

0